To the best of our knowledge, the following study is the first to propose new areas of interest for CBG’s medical use in obesity-related complications therapy, demonstrating that CBG treatment has a positive effect on the intramuscular phospholipids fraction by changing the content of individual PLs subclasses and modifying their FAs composition, which is associated with the attenuation of local inflammatory response in the skeletal muscle of insulin-resistant rats subjected to a high-fat, high-sucrose diet. The gene discussed is INS; the disease is Obesity.